AstraZeneca Plc said on Tuesday it is working with Oxford University to produce a vaccine for the Omicron coronavirus variant, joining other vaccine-makers who are looking to develop the variant-specific vaccine, reports Reuters.
"Together with Oxford University, we have taken preliminary steps in producing an Omicron variant vaccine, in case it is needed and will be informed by emerging data," a spokesperson for the company said in a statement.
Oxford did not immediately respond to a request for comment outside business hours.
The Financial Times first reported the news, citing Sandy Douglas, a research group leader at Oxford.
"Adenovirus-based vaccines (such as that made by Oxford/AstraZeneca) could in principle be used to respond to any new variant more rapidly than some may previously have realised," Douglas told FT.
A lab study last week found that AstraZeneca's antibody cocktail Evusheld retained neutralising activity against the Omicron variant